Wegovy 1.2mg: why this dose doesn't exist on the UK schedule

You've seen '1.2mg' somewhere and now you're not sure what you were reading

It's an easy thing to stumble across. Weight-loss forums, social media posts and some overseas pharmacy listings throw out milligram figures that don't match what a UK prescriber would ever write on your prescription. The most likely explanation is a mix-up with Ozempic. Both Wegovy and Ozempic contain semaglutide, made by Novo Nordisk, but they are licensed for different purposes. Ozempic's titration schedule does pass through a 1.0mg and a 2.0mg maintenance dose in the UK, and some international versions include a 1.2mg step, so that number occasionally bleeds into UK conversations.

The other possibility is that something described as 1.2mg Wegovy was never a legitimate UK product at all. The MHRA has warned publicly about counterfeit and unlicensed weight-loss injectables circulating online; a product with a non-existent dose description is exactly the sort of detail that should give you pause. You can check whether any online pharmacy dispensing Wegovy is properly registered using the GPhC pharmacy register.

Whatever brought you here, the short answer is the same: 1.2mg is not a Wegovy dose in the UK, and no legitimate prescriber would write it.

The doses that do exist, and why the steps are set where they are

The Wegovy semaglutide treatment licensed in the UK runs through five dose levels: 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg. The NHS medicines page for semaglutide describes the standard titration schedule in full, and your prescriber will map a plan to it based on how your body responds. Each step typically lasts around four weeks before a prescriber reviews whether you're tolerating the current dose and whether it's appropriate to go up.

The reason those specific steps exist is pharmacological. Semaglutide slows gastric emptying and acts on GLP-1 receptors involved in appetite and satiety. Starting at a low dose and moving gradually gives the gut time to adjust, which reduces the intensity and duration of nausea, the most commonly reported side effect. Jumping ahead (or being supplied a dose outside the schedule) removes that protective ramp.

The 2.4mg maintenance dose was the standard ceiling for several years. Since January 2026, the MHRA has also approved a 7.2mg dose for adults with a BMI of 30 or above, initially delivered as three 2.4mg pens weekly and later as a dedicated single-dose pen approved in April 2026. That higher dose is still prescribed and titrated by a clinician; it doesn't change the starting point or the standard steps below it. You can read more on the semaglutide overview page if you want the background on how the medicine works before discussing doses with a prescriber.

How Ozempic's 1.2mg dose causes the confusion

Ozempic is also semaglutide, also made by Novo Nordisk, but its licence in the UK is for type 2 diabetes, not weight management. The NHS medicines information for semaglutide explains both products clearly. Ozempic's schedule in some countries includes a 1.2mg dose as an intermediate step between 0.5mg and the 1.0mg maintenance dose used in diabetes management. That step doesn't appear in the UK's Wegovy titration schedule, and Ozempic is not prescribed for weight loss, full stop.

If a source is telling you to take 1.2mg of Wegovy, they are either confusing two different products, describing a non-UK labelling convention, or selling something that doesn't correspond to any authorised UK medicine. None of those are situations where you want to be putting a needle in.

Some people searching for the 1.0mg Wegovy step land on 1.2mg results instead, so the confusion also has a simple typing explanation. If you're currently at 1.0mg and wondering what comes next, the answer is 1.7mg, not 1.2mg, and the timing of that move is your prescriber's call, not something to self-manage based on what you've read. Our Wegovy 1.0mg guide covers what to expect at that stage of the titration and what your prescriber will be looking for before recommending an increase. Similarly, if you've seen references to a 1.25mg semaglutide dose in your research, that figure belongs to a different medicine entirely and is not part of the Wegovy schedule.

Thinking about where to go from here

If you're researching Wegovy because you're trying to work out whether it could be suitable for you, the most useful next step is a clinical conversation rather than more dose research. The schedule is fixed; what varies is whether you're eligible, how well you tolerate each step, and how your prescriber monitors your progress. Wegovy is a prescription-only medicine, and the prescriber's job is precisely to guide those decisions.

Eligibility for Wegovy follows criteria set out in the medicine's UK licence: broadly, adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. The NICE appraisal for semaglutide sets narrower criteria for NHS access, including a requirement that treatment happens within a specialist weight management service for a maximum of two years. Private prescribing follows the licensed criteria, assessed individually. Before you think too hard about which dose you might end up on, it's worth understanding what weight-loss treatment options are available to you and which might fit your situation.

One thing that patients tell us they wish they'd known earlier: the dose you end up on isn't a measure of how well you're doing. Some people stay at 1.0mg and see good results; others need to reach 2.4mg before appetite suppression really settles. There's no 1.2mg shortcut in between, and you wouldn't want one. For a sense of what private treatment involves (including how cost breaks down across the titration) the Wegovy price comparison page explains what the different doses typically cost through private providers. If you're ready to talk through eligibility, our prescribers are available seven days a week.